-
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
NASDAQ: $REGN TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and… Source: Read More
-
New Hope for Advanced Low-Grade Serous Ovarian Cancer: The Potential of Ubamatamab
NASDAQ: $REGN A Breakthrough in Ovarian Cancer Research Recent clinical findings have brought a glimmer of optimism for patients battling advanced low-grade serous ovarian cancer. A novel therapeutic agent known as ubamatamab (MUC16xCD3) has shown promising results in initial clinical trials, highlighting a potential new path forward for those who have exhausted standard treatment options.…
-
A Breakthrough in Rare Disease Care: FDA Approves Pasatru (garetosmab) for FOP
NASDAQ: $REGN A New Chapter for FOP Patients For individuals living with Fibrodysplasia Ossificans Progressiva (FOP), a rare and debilitating genetic disorder, the medical landscape has just shifted significantly. The FDA has officially approved Pasatru (garetosmab), a new therapeutic option designed to help manage this challenging condition. Understanding FOP FOP is a rare genetic condition…